Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy

Abstract

The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compounds to demonstrate in vivo potency by targeting a step in viral entry. T-20 inhibits a conformational change in the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein (gp41) that is required for fusion between HIV-1 and target cell membranes. The initial phase I clinical trial of T-20 treatment for HIV-infected patients thus provided a unique opportunity to evaluate the emergence of resistant virus in vivo to this novel class of antiretroviral agents. All four patients who received an intermediate dose of T-20 (30 mg twice daily) had an initial decline in plasma viral load over the first 10 days but a rising trend by day 14, suggestive of selection for resistant virus. Plasma virus derived from patients enrolled in all dosage groups of the phase I T-20 trial was analyzed by population sequencing before and after treatment. While no mutations were found within a highly conserved 3-amino-acid sequence (GIV) known to be critical for fusion at baseline, after 14 days of therapy, virus from one patient in the 30-mg dose group (30-1) developed a mutation in this motif, specifically an aspartic acid (D) substitution for glycine (G) at position 36. Multiple env clones were derived from the plasma virus of all four patients in the 30-mg dosage group. Sequence analysis of 49 clones derived from the plasma of patient 30-1 on day 14 revealed that 25 clones contained the G36D mutation, while 8 contained the V38A mutation. Dual mutations involving G36D and other residues within the HR1 domain were also identified. In 5 of the 49 env clones, other mutations involving residues 32 (Q32R or Q32H) and 39 (Q39R) were found in combination with G36D. Cloned env sequences derived from the plasma virus of subject 30-3 also had single mutations in the GIV sequence (V38M and I37V) detectable following therapy with T-20. The plasma virus from subjects 30-2 and 30-4 did not contain changes within the GIV sequence. To analyze the biological resistance properties of these mutations, we developed a novel single-cycle HIV-1 entry assay using JC53BL cells which express ␤-galactosidase and luciferase under control of the HIV-1 long terminal repeat. Full-length env clones were derived from the plasma virus of patients 30-1 and 30-3 and used to generate pseudotyped virus stocks. The mean 50% inhibition concentrations (IC 50 s) for mutants G36D and V38A (patient 30-1) were 2.3 g/ml and 11.2 g/ml, respectively, statistically significant increases of 9.1-and 45-fold, respectively, compared with those of wild-type Env. The IC 50 for the V38 M mutation (patient 30-3) was 7.6 g/ml, an 8-fold increase compared with that of the wild type. The I37V mutation resulted in an IC 50 3.2-fold greater than that of the wild type. Envs with double mutations (Q32R plus G36D and Q32H plus G36D) exhibited a level of resistance similar to that of G36D alone. These findings provide the first evidence for the rapid emergence of clinical resistance to a...

Role of the Envelope Genetic Context in the Development of Enfuvirtide Resistance in Human Immunodeficiency Virus Type 1-Infected Patients

“…Similar to results with other antiviral agents, however, ENF-resistant HIV-1 variants may emerge under the selective pressure of ENF (26,32,39,42) whenever the treatment fails to completely suppress viral replication in vivo. Understanding the determinants of, and the constraints to, the development of resistance to ENF is essential for the optimization of the clinical use of this new class of inhibitors.…”

“…ENF binding to HR1 is thought to compete with the folding of the HR2 domain onto HR1, thus preventing Env-mediated membrane fusion (1,5,17). Accordingly, viral variants selected both in vitro and in vivo in the presence of ENF carry resistance mutations in the HR1 domain (35,42). Mutations in HR2 have also been described in virus from treated patients and are thought to exert a compensatory role through reinforcement of the interaction between HR1 and HR2 in the context of a mutated HR1 (2,25,46).…”

Leukotriene B4 Triggers the In Vitro and In Vivo Release of Potent Antimicrobial Agents

“…Viral infectivity was then determined by adding the solutions to the wells of a 96-well plate coated with TZM-bl indicator cells (30). Virions were allowed to infect cells for 1 h after which the wells were washed twice with PBS followed by the addition of 0.2 ml of culture medium.…”

Polymeric Anti‐HIV Therapeutics

“…[28] In addition, one of the consequences of high and frequent administration is the emergence of T-20 resistant strains of HIV. [37] 3.3. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs and NtRTIs) Seven nucleoside reverse transcriptase inhibitors (NRTIs) have been licensed for marketing (Figure 4), however the production of zalcitabine (ddC) has been discontinued due to the production of more effective replacement NRTI drugs.…”

“…Wang et al reported multivalent oligomannose dendrons conjugated via copper catalyzed 'click' chemistry to first, second and third generation alkyne functionalized dendritic scaffolds that were shown to bind to DC-SIGN expressing cells. [123] Using glycan microarrays for direct interactions and competition assays with IgG 2G12 (an antibody that targets the glycans on gp120), these authors demonstrated that the dissociation constant of multivalent oligomannose dendrons (37) inversely correlated to an increase dendrimer generation as well as to the number of mannose units (Man 4 or Man 9 ). Although the in vitro assays demonstrated the nanomolar binding affinities due to multivalency of the glycodendrons, evidence for HIV-1 inhibition by trans-infection was not shown.…”